Previous Article | Next Article 
Journal of Virology, August 2000, p. 7238-7249, Vol. 74, No. 16
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mapping and Characterization of the N-Terminal I
Domain of Human Immunodeficiency Virus Type 1 Pr55Gag
Stephanie
Sandefur,
Rita M.
Smith,
Vasundhara
Varthakavi, and
Paul
Spearman*
Departments of Pediatrics and Microbiology and Immunology,
Vanderbilt University School of Medicine, Nashville, Tennessee
Received 18 January 2000/Accepted 22 May 2000
 |
ABSTRACT |
Human immunodeficiency virus (HIV) type 1 particles assemble at the
plasma membrane of cells in a manner similar to that of the type C
oncoretroviruses. The Pr55Gag molecule directs the assembly
process and is sufficient for particle assembly in the absence of all
other viral gene products. The I domain is an assembly domain that has
been previously localized to the nucleocapsid (NC) region of Gag. In
this study we utilized a series of Gag-green fluorescent protein (GFP)
fusion proteins to precisely identify sequences that constitute the
N-terminal I domain of Pr55Gag. The minimal sequence
required for the I domain was localized to the extreme N terminus of
NC. Two basic residues (arginine 380 and arginine 384) within the
initial seven residues of NC were found to be critical for the function
of the N-terminal I domain. The presence of positive charge alone in
these two positions, however, was not sufficient to mediate the
formation of dense Gag particles. The I domain was required for the
formation of detergent-resistant complexes of Gag protein, and confocal
microscopy demonstrated that the I domain was also required for the
formation of punctate foci of Gag proteins at the plasma membrane.
Electron microscopic analysis of cells expressing Gag-GFP fusion
constructs with an intact I domain revealed numerous retrovirus-like
particles (RVLPs) budding from the plasma membrane, while I
domain-deficient constructs failed to generate visible RVLPs. These
results provide evidence that Gag-Gag interactions mediated by the I
domain play a central role in the assembly of HIV particles.
 |
INTRODUCTION |
Human immunodeficiency virus (HIV)
particle assembly takes place at the plasma membrane of infected cells.
Pr55Gag is a polyprotein precursor derived from the HIV
gag gene that forms the major core components of the virus
particle. Pr55Gag, when expressed in the absence of all
other viral components, is sufficient to generate retrovirus-like
particles (RVLPs) which bud from the plasma membrane in a manner
essentially identical to that of infectious virions. The Gag
polyprotein thus contains sufficient intrinsic capacity to allow its
transport from cytoplasmic sites of translation to the plasma membrane,
where it engages additional Gag molecules, interacts with plasma
membrane components, and directs the particle budding process (10,
19, 32, 37). The viral protease is activated during the budding
process and subsequently cleaves Pr55Gag into the following
components (listed in order of their occurrence from N to C terminus):
matrix (MA), capsid (CA), spacer peptide 1 (SP1), nucleocapsid (NC),
spacer peptide 2 (SP2), and p6. Three assembly domains which are common
to the Gag polyproteins of lentiviruses, oncoretroviruses, and
spumaviruses have been described. The membrane interaction (M) domain
is required for transport to and interaction with the plasma membrane
of cells. In the case of most retroviral Gag proteins, including HIV,
the M domain requires a myristic acid modification of the N-terminal
glycine residue of Gag acting in concert with a series of basic amino
acids located within the MA region (17, 42). Some
retroviruses, such as Rous sarcoma virus (RSV), lack the myristic acid
modification of MA yet still have a functional M domain which is
located within the N-terminal two-thirds of MA (8, 34, 38).
The interaction (I) domain is a functional domain required for the
assembly of particles of normal density (1.16 to 1.18 g/ml) (12,
27). This domain is located within NC and is present in at least
two copies in the case of HIV and RSV (1). The late (L)
domain is required for particle budding and is a determinant of
retroviral particle size (13, 27). When L domain function is
abrogated in the context of a full-length provirus, particles are
generated normally at the plasma membrane of transfected cells but are
inefficiently released (16).
While the M, I, and L domains represent distinct assembly domains
within retroviral Gag polyproteins, additional assembly functions
within HIV type 1 (HIV-1) Gag are located outside of these domains. The
CA region contains a dimerization domain which has been shown to be
essential for Gag-Gag interaction when in vitro assembly systems are
employed (15, 36, 39). Some point mutations within the major
homology region (MHR) of HIV-1 CA create severe defects in assembly
(23), and numerous mutations within CA positioned C terminal
to the MHR that result in elimination or severe reduction of particle
assembly have been described previously (7, 20, 28, 35, 40).
Thus, the domains designated M, I, and L are useful for conserved
functional retroviral assembly domains but do not encompass all
necessary assembly functions located within HIV-1 Pr55Gag.
The I domain of HIV Gag was first localized to the NC region by Bennett
and coworkers, who demonstrated that two distinct fragments of HIV-1 NC
could restore dense particle formation to an RSV Gag molecule which by
itself resulted in the formation of only light-density particles
(1). Their work established that the I domain is conserved
functionally among retroviral Gag proteins and that it is redundant
within NC. I domains have more recently been described for murine
leukemia virus and for human foamy virus (2). Although the
HIV-1 NC fragments initially report to contain a functional I domain
each contained a zinc finger motif, it is clear that a zinc finger is
not required for I domain function. This is best exemplified by the
demonstration that human foamy viruses, which contain no zinc finger
motif, have at least two identifiable I domains (2). At the
same time, it was demonstrated that the addition of a simple string of
basic residues could reconstitute I domain function in the context of an I domain-deficient RSV Gag molecule. Members of our group have demonstrated that the HIV-1 I domain does not require the presence of a
zinc finger motif and that I domain function in the context of serially
C-terminally truncated Gag proteins is localized to the N-terminal
subdomain of NC (29). Two additional findings correlated
closely with the mapping of the I domain by particle density
determination: (i) the efficiency of Gag protein membrane binding and
(ii) a peripheral, punctate localization of Gag within cells, as seen
by confocal microscopy. These studies suggested to us that a further
understanding of the I domain may provide important additional insights
into the mechanisms of HIV particle assembly.
In this study, we sought to identify more precisely the residues within
the N-terminal subdomain of NC which are required for I domain
function, as well as to define the contribution of downstream sequences
of NC in the context of N-terminal I domain mutations. The N-terminal I
domain was mapped to the extreme N-terminal seven amino acids of NC,
and two key arginine residues were identified. Although this small
sequence is sufficient to reconstitute normal particle density,
additional sequences within the N-terminal subdomain, first zinc
finger, basic linker region, and second zinc finger enhance I domain
function, as indicated by quantitative subcellular fractionation
analysis and confocal microscopic analysis.
 |
MATERIALS AND METHODS |
Construction of plasmids expressing Gag-GFP fusion proteins.
The Gag coding sequence for all constructs was derived from the HXB2gpt
proviral clone. The construction of expression plasmids for the fusion
proteins designated 55GAG/GFP, MACA/GFP, GAG377/GFP, GAG391/GFP,
GAG405/GFP, GAG411/GFP, and MA/GFP has been previously described
(29). Additional Gag-green fluorescent protein (GFP) constructs were constructed for the purposes of this study. The GFP
sequence was taken from plasmid pEGFP-N1, pEGFP-N2, or pEGFP-N3 (Clontech, Palo Alto, Calif.). Plasmid pTM1 was used as the backbone expression plasmid for all constructs. All of the gag gene
fragments, except 55GAG(R380,384A)/GFP, were generated via PCR using
primers that introduced an NcoI site at the 5' ATG site and
a BamHI site at the 3' fusion site. The resulting PCR
fragments were ligated into pTM1, using the NcoI and
BamHI sites found in the polylinker region. GFP cassettes
were then digested with BamHI-NotI and ligated into BamHI-EagI-digested intermediate Gag
constructs to generate fusions in the appropriate reading frame. All
PCR-generated gag gene fragments were verified to be correct
by sequencing of the complete gag gene insert within the
expression plasmid. The expression plasmid design allows for the
expression of full-length MA fused to GFP (MA/GFP), full-length Gag
fused to GFP (55GAG/GFP), a GFP fusion at the end of the SP1 region
between CA and NC (GAG377/GFP), and a series of Gag-GFP fusions created
at serial sites within the NC region (GAG384/GFP, GAG391/GFP,
GAG405/GFP, GAG411/GFP, GAG426/GFP, and GAG432/GFP). The number in each
construct designation represents the most C-terminal gag
codon present, with the numbering beginning with the gag
initiator ATG. Fusion breakpoints within NC are illustrated
diagrammatically in Fig. 1.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of Gag-GFP constructs
subdividing HIV-1 NC. Asterisks indicate the sites of Gag truncation
and GFP fusion. The number represents the C-terminal amino acid residue
expressed, with the Gag initiator methionine considered residue 1. The
shaded box highlights the minimum sequence required for I domain
function as discussed in the text. The stars indicate the two key
arginine residues (R380 and R384) that were mutated to abrogate the
function of the N-terminal I domain, creating the series of N-terminal
I domain mutant constructs. Note that the constructs containing the
double arginine-to-alanine mutation are designated by the number of the
residue at the truncation site (GFP fusion site) followed by the
designation R380/384A in parentheses. For example, GAG405/GFP
containing the double arginine-to-alanine mutation is designated
GAG405(R380/384A)/GFP. Arrows, HIV protease cleavage sites.
|
|
Oligonucleotides used in the construction of the Gag expression
plasmids described above were AGAGCCATGGGTGCGAGAGCGTCAGTA [forward primer for all Gag-GFP constructs except
55GAG(R380,384A)/GFP], CGCGGATCCCGTAATTTTGGCTGACCTGATT
(reverse primer for MA/GFP),
CGGGATCCATTATGGTAGCTGAATTTG (reverse primer for
Gag377/GFP), CGGGATCCTAAAATTGCCTCTCTGCAT (reverse primer for Gag384/GFP), GGTGGATCCCTTAACAATCTTTCTTTG (reverse
primer for Gag391/GFP), GGTGGATCCGCAATTTCTGGCTGTGTG (reverse
primer for Gag405/GFP), GGTGGATCCCTTTTTCCTAGGGGCCCTG
(reverse primer for Gag411/GFP),
GGTGGATCCACAATCTTTCATTTGGTGTCC (reverse primer for Gag426/GFP), and GCGGATCCATTAGCCTGTCTCTCAGTACAATCTTTCATTTGGTG (reverse primer for Gag432/GFP).
Construction of plasmids expressing Gag-GFP fusion proteins
containing amino acid mutations within the N-terminal I domain.
Arginine 380 and arginine 384 were mutated to alanine in the context of
55GAG/GFP using overlap-extension PCR with the following primers:
ATAATGATGCAGGCCGGCAATTTTGCGAACCAAAGAAAG [inside forward primer for 55GAG(R380,384A)/GFP],
TTTCTTTGGTTCGCAAAATTGCCGGCCTGCATCATTATG [inside
reverse primer for 55GAG(R380,384A)/GFP],
AAGCTGCAGAATGGGATAG [outside forward primer for
55GAG(R380,384A)/GFP], and CCAGATCTTCCCTAAAAAATTAGC [outside reverse primer for 55GAG(R380,384A)/GFP]. The final
PCR product was digested with PstI and BglII and
ligated into 55GAG/GFP to create the 55GAG(R380,384A)/GFP plasmid.
These same mutations were then generated in the context of the
GAG384/GFP construct. In addition, the two arginine codons were
individually mutated (R380A and R384A), and lysine was substituted for
both residues (R380,384K). This was achieved using a PCR reaction with
HXB2gpt as the template, the forward primer listed in the section
above, and the following reverse primers:
CGGGATCCGCAAAATTGCCGGCCTGCATCATTATGGTAGC [reverse
primer for GAG384(R380,384A)/GFP],
CGGGATCCTAAAATTGCCGGCCTGCATCATTATGGTAGC [reverse primer for
GAG384(R380A)/GFP], CGGGATCCGCAAAATTGCCTCTCTGCATACATTATGGTAGC [reverse primer for GAG384(R384A)/GFP], and
GCGGATCCCTTAAAATTGCCTTTCTGCATCATTATGGTAGC [reverse primer
for GAG384(R380,384K)/GFP]. Generation of the NC constructs containing
the double arginine-to-alanine mutations with sequential addition of NC
subdomains was then accomplished via PCR using the 55GAG(R380,384A)/GFP
plasmid as a template and the reverse primers listed above for
construction of the sequential fusion sites within NC.
Expression of Gag-GFP fusion proteins.
The vaccinia virus-T7
RNA polymerase system was used to express Gag-GFP fusion proteins in
the African green monkey kidney cell line BSC-40 as previously
described (29-31). T7 RNA polymerase was provided by
infection of the cells with 10 PFU of the recombinant vaccinia virus
VTF 7-3 per cell. Following infection, cells were transfected with the
appropriate plasmid using a liposome-mediated transfection protocol.
Equilibrium density measurements of Gag-GFP pseudovirion
particles.
Gag-GFP fusion proteins were produced in BSC-40 cells
as described above. Culture medium was removed 3 to 4 h
posttransfection and replaced with Dulbecco's modified Eagle medium
deficient in cysteine and methionine and supplemented with 75 µCi of
[35S]cysteine-methionine per ml. Following an overnight
incubation, supernatants were collected, filtered through a
0.45-µm-pore-size syringe filter, layered on a 20% sucrose cushion
in NTE (100 mM NaCl, 10 mM Tris-Cl [pH 8.0], 1 mM EDTA), and
subjected to centrifugation at 100,000 × g for 3 h. The medium and cushion were removed; the pelleted material was
resuspended in NTE and layered on the top of a linear 20 to 60%
(wt/vol) sucrose gradient. The gradient was subjected to centrifugation
at 100,000 × g for 16 to 20 h, after which 20 equal fractions were collected. The precise refractive index of each
fraction was determined using a refractometer, which allowed
calculation of the sucrose density of each fraction. The remainder of
the fractions were immunoprecipitated using pooled HIV-positive patient
sera and separated via sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), followed by autoradiographic analysis. Each
gradient presented is representative of a minimum of two gradient
fractionations, in which the peak densities shown were identical.
Subcellular fractionation and quantitation of protein.
BSC-40 cells grown in 100-mm3 plates and expressing Gag-GFP
fusion proteins were harvested 16 h posttransfection and processed for differential sedimentation centrifugation as previously described (29). Briefly, cells from one dish were subjected to Dounce homogenization in 1 ml of hypotonic buffer (10 mM Tris-Cl [pH 8.0], 1 mM EDTA) with protease inhibitors and then centrifuged at
1,000 × g for 10 min to remove nuclei and unbroken
cells. Supernatants containing cytosolic components and cellular
membranes were subjected to ultracentrifugation at 100,000 × g for 30 min at 4°C. Soluble fractions and membrane pellets
were analyzed by fluorescence spectrophotometry. Supernatants and
pellets were adjusted to 0.5% Triton X-100 in NTE buffer prior to
measurement, and vigorous vortexing or pipetting was performed to
ensure uniform resuspension of pelleted components. Standards of
serially diluted recombinant enhanced green fluorescent protein (EGFP;
Clontech) were prepared in the same solution and analyzed together with
experimental samples. These standards were utilized to generate a
standard curve. The fluorescence intensities of the Gag-GFP samples and
of the standards were determined with a VersaFluor Fluorometer
(Bio-Rad, Hercules, Calif.), with excitation and emission filters being
450 nm and 510 nm, respectively. The percentage of sedimented Gag
protein in each experiment was calculated as the amount of protein in
the membrane pellet/(the amount of protein in the pellet plus the
amount of protein in the soluble fraction).
Subcellular fractionation into detergent-resistant
complexes.
Cells were transfected and harvested as described
above, with the following modifications. S1 supernatants were adjusted
to 0.5% Triton X-100 prior to the centrifugation step. After
centrifugation at 100,000 × g, the membranes and the
proteins associated with those membranes were found in the soluble
fraction, leaving detergent-resistant components in the pellet
fraction. Quantitation was performed by fluorescence spectrophotometry
as described above.
Electron microscopy.
Gag-GFP fusion proteins were expressed
as described above. Cells were harvested 12 h following
transfection and fixed in 2% gluteraldehyde in phosphate buffer,
postfixed with 1% osmium tetroxide, stained with 1% uranyl acetate,
dehydrated in ethanol, and embedded in Spurr resin. Thin sections were
cut with an ultramicrotome and analyzed on a Philips model 3000 electron microscope. In this manner, the following five Gag-GFP
expression constructs were examined for particle formation: 55GAG/GFP,
GAG384/GFP, GAG384(R380,384A)/GFP, GAG377/GFP, and MA/GFP. The entire
grid, representing hundreds of individual fields, was examined for each construct.
 |
RESULTS |
Identification of the minimal I domain within the N-terminal
subdomain of NC.
In order to identify the minimal region within
the N-terminal subdomain of NC that contains I domain function, a panel
of Gag truncation constructs fused to GFP was generated (Fig. 1). Gag-GFP particles were harvested from cellular supernatants, pelleted through a 20% sucrose cushion, and subjected to equilibrium density centrifugation on a linear sucrose gradient. Equal fractions were collected, immunoprecipitated with pooled HIV patient sera, and analyzed using SDS-PAGE. It should be noted that the gradients shown
are representative of at least two independent experiments. 55GAG/GFP
produced particles with a peak density of 1.17 g/ml (Fig.
2A), consistent with an
earlier report by members of our group (29). MA/GFP, which
consists of the matrix region fused to GFP, was released, pelleted
through sucrose, and reached an equilibrium density of 1.13 g/ml (Fig.
2B). GAG377/GFP, which contains the MA, CA, and SP1 regions of Gag
fused to GFP, was demonstrated to form particles of a similar light
density of 1.13 g/ml (Fig. 2C). The inclusion of the N-terminal seven
amino acids of NC (amino acids 378 to 384 [Fig. 1]) produced a
dramatic shift in Gag-GFP particle density. GAG384/GFP produced
particles of a normal density, 1.17 g/ml (Fig. 2D). Scanning
densitometry of the autoradiograms derived from GAG384/GFP and
GAG377/GFP particle gradients was employed to illustrate the clear
separation between the peak fractions of GAG377/GFP and GAG384/GFP
(Fig. 2E). The peak for dense particles was found in fractions 5 to 7, corresponding to a density of 1.17 to 1.16 g/ml; the peak for light
particles was found in fractions 9 to 11, corresponding to a density of 1.13 to 1.12 g/ml. The sucrose densities from each fraction of the
experiments represented in Fig. 2C and D are nearly identical, as
indicated in Fig. 2E by overlap of their plotted densities. The shift
in production of particles with a light density to that of a normal
density therefore occurred with the addition of the N-terminal seven
amino acids of NC. Based on the definition of the I domain as a density
determinant, this small region in NC constitutes a functional I domain.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Equilibrium density of Gag-GFP particles defining the
N-terminal I domain. (A) 55GAG/GFP; (B) MA/GFP; (C) GAG377/GFP; (D)
GAG384/GFP. Following overnight labeling with
[35S]cysteine-methionine, supernatants were collected,
layered on a 20% sucrose cushion, and subjected to centrifuga- tion. Pelleted material was layered on top of a linear 20 to
60% sucrose gradient and centrifuged to equilibrium. Twenty equal
fractions were collected, immunoprecipitated using pooled HIV-positive
patient sera, and analyzed by SDS-PAGE followed by autoradiography. The
densities of the peak fractions are indicated above each autoradiogram
by the arrow(s). Lanes M, molecular mass markers (molecular mass in
kilodaltons is indicated at the left of each autoradiogram in panels A
to D). The closed circle in panel A is above the lane containing a
fraction with a density of 1.16 g/ml. (E) Plot of densitometry results
and sucrose densities representing the autoradiograms of panels C and
D. Black squares, relative absorbance of bands seen in the GAG384/GFP
autoradiogram; grey diamonds, relative absorbance of bands seen in the
Gag377/GFP autoradiogram; open squares, sucrose densities of the
fractions in the GAG377/GFP experiment; open diamonds, sucrose
densities of fractions from the GAG384/GFP experiment. Relative
absorbance values were obtained by scanning the autoradiograms shown in
panels B and C, followed by pixel quantitation with National Institutes
of Health Image software (version 1.61).
|
|
Characterization of the N-terminal I domain.
Several previous
reports have demonstrated that the N-terminal basic region of NC is of
particular importance in the assembly and release of HIV particles
(14, 18, 20). Basic residues placed C-terminal to CA have
been shown to be sufficient to restore particle density to an RSV Gag
construct lacking the I domain (2). We noted that the
sequence of the minimal I domain defined above
(378MQRGNFR384) includes two arginine residues.
To examine the importance of these residues in the function of the I
domain, R380 and R384 were mutated to alanine either singly or
together. The double mutant was constructed in the context of both the
minimal I domain construct, GAG384/GFP, and the full-length construct
55GAG/GFP, resulting in the constructs GAG384(R380,384A)/GFP and
55GAG(R380,384A)/GFP, respectively. Each arginine was also mutated
individually in the context of GAG384/GFP, resulting in the constructs
Gag384(R380A)/GFP and Gag384(R384A)/GFP. To test for I domain
function of these mutants, the density of the released Gag-GFP
particles was determined by equilibrium density centrifugation.
Parental GAG384/GFP particles peaked at a normal density of 1.17 g/ml
(Fig. 3A shows the results from an
experiment separate from that whose results are pictured in Fig. 2D).
Mutation of the two arginine residues in the context of GAG384/GFP had
a dramatic affect on the particle density. GAG384(R380,384A)/GFP, which
contains the double mutation, produced particles of a very light
density, 1.11 g/ml (Fig. 3B). 55GAG(R380,384A)/GFP, the construct
containing the double mutation in the context of the full-length Gag,
produced particles of normal density (1.16 g/ml) (Fig. 3C). This result
demonstrates that I domain function is redundant within NC, which is
consistent with previous findings (1, 2, 29). However, in
repeated experiments, the particles produced by
55GAG(R380,384A)/GFP never attained the peak density of the
55GAG/GFP particles (1.17 g/ml), suggesting that even in this context
the loss of the N-terminal I domain slightly altered the packing of Gag
molecules.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of mutation of arginine residues 380 and 384 upon
particle density. The density of the Gag-GFP particles for the
N-terminal I domain mutants was determined as described in the legend
for Fig. 2. The effects of site-directed mutagenesis of R380 and R384
were examined in the context of truncated Gag (GAG384/GFP) and in the
context of full-length Gag (55GAG/GFP). (A) GAG384/GFP; (B)
GAG384(R380/384A)/GFP; (C) 55GAG(R380/384A)/GFP; (D)
GAG384(R380/384K)/GFP; (E) GAG384(R380A)/GFP; (F) GAG384(R384A)/GFP.
Arrows, peak fractions (with densities as indicated).
|
|
Our results suggested that arginine 380 and arginine 384 play a crucial
role in N-terminal I domain function. To examine whether a positive
charge in positions 380 and 384 is sufficient for I domain function,
both arginines were changed to lysine in the context of the Gag384/GFP
construct, generating Gag384(R380,384K)/GFP. The particles produced
from this construct demonstrated an intermediate density of 1.14 g/ml
(Fig. 3D). Individual arginine-to-lysine mutations at these positions
were not examined. Thus, the presence of positive charge itself in
these positions was not sufficient to restore normal retroviral
particle density. Next, individual arginine-to-alanine mutations were
examined for effects on particle density in the context of GAG384/GFP.
GAG384(R380A)/GFP produced particles of an intermediate density, 1.14 g/ml, whereas Gag384(R384A)/GFP produced particles of a light density,
1.11 g/ml (Fig. 3E and F, respectively).
Localization of the C-terminal I domain.
In order to identify
additional regions within NC harboring I domain function, sequential
additions of NC subdomains were constructed in the context of
N-terminal I domain mutations. The R380,384A mutations were introduced
into the set of NC truncation constructs shown in Fig. 1, generating
the following constructs: GAG391(R380,384A)/GFP, which contains the
N-terminal region of NC; GAG405(R380,384A)/GFP, which includes the
addition of the first zinc finger; GAG411Gag(R380,384A)/GFP, which
includes the addition of the basic linker region;
GAG426(R380,384A)/GFP, which includes the addition of the second zinc
finger; and GAG432(R380,384A)/GFP, which contains the entire NC region.
Using particle density as an assessment of I domain function, we sought
to determine which region of NC, when added back to the minimal I
domain mutant, would restore dense particle formation. The results are
shown in Fig. 4. GAG384(R380,384A)/GFP
particles attained a light equilibrium density as has already been
shown in this report (Fig. 4A; these results are from a separate
experiment from that represented in Fig. 3B and are included to
facilitate comparisons with the autoradiograms in Fig. 4B through F).
Addition of the remaining portion of the N-terminal region of NC
partially restored dense particle formation (Fig. 4B). Although the
peak reached a normal density of 1.16 g/ml, the particle band was quite
broad in repeated experiments and extended into the light-density range
(Fig. 4B). There are three basic residues in the region that was added
between positions 384 and 391, again suggesting that basic charge may
have played some role in enhancing particle density. With the addition
of the first zinc finger, GAG405(R380,384A)/GFP, the particle
density was restored to normal (Fig. 4C). Further addition of the basic linker region, the second zinc finger, and the C-terminal subdomain of
NC did not significantly alter particle density (Fig. 4D to F).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
Determination of buoyant density of NC N-terminal I
domain mutants. The density of the Gag-GFP particles was determined as
described in the legend for Fig. 2. The line diagrams above the
autoradiograms represent regions of NC included in the representative
construct; each pair of X's denotes the arginine-to-alanine double
mutation (R380,384A). Each bracket denotes the fractions associated
with dense RVLPs (1.16 to 1.18 g/ml), and the arrows indicate the peak
fractions (the corresponding sucrose density is provided). Lanes M,
molecular mass markers (molecular mass in kilodaltons is indicated at
the left). (A) GAG384(R380/384A)/GFP; (B) GAG391(R380/384A)/GFP; (C)
GAG405(R380/384A)/GFP; (D) GAG411(R380/384A)/GFP; (E)
GAG426(R380/384A)/GFP; (F) GAG432(R380/384A)/GFP.
|
|
Role of the I domain in formation of detergent-resistant Gag
protein complexes.
Previous results generated in our laboratory
have demonstrated that the I domain contributes substantially to the
efficiency of membrane binding as measured by differential
sedimentation centrifugation (29). However, these previous
experiments did not examine the effect of the I domain upon Gag protein
sedimentation in the presence of detergents. For Gag proteins, this may
be particularly important, as intracellular Gag protein complexes which
are resistant to detergent have been identified within HIV-infected
cells and have been recently proposed to represent assembly
intermediate structures (21, 22). We therefore performed
experiments to determine if the I domain is responsible for the
formation of detergent-resistant complexes of Gag protein. Membrane-
and cytoskeleton-enriched fractions were separated from cytosolic
components by differential sedimentation centrifugation following
osmotic lysis in the absence of detergent. The precise amount of
Gag-GFP fusion protein present in each fraction was determined by
fluorescence spectrophotometry, using recombinant GFP to generate a
standard curve. The results were plotted as the percentage of Gag
protein in pelleted fractions versus total Gag protein (in soluble plus
pelleted fractions). As previously reported, the full-length construct
55GAG/GFP sedimented much more efficiently than did MA/GFP (Fig.
5A). Extension of the Gag sequence to
include MA, CA, and SP1 (GAG377/GFP) led to a small increase in the
percentage of Gag protein in the membrane-enriched pellet. Addition of
the seven amino acids of the N-terminal I domain (represented by
GAG384/GFP) led to a significant increase in the percentage of
sedimented Gag protein (P = 0.012 by Student's t test for GAG377/GFP versus GAG384/GFP). There was not a
significant further increase in the differential sedimentation results
for the remaining constructs, although the mean percentages were
slightly higher for GAG411/GFP, GAG426/GFP, GAG432/GFP, and 55GAG/GFP.


View larger version (98K):
[in this window]
[in a new window]
|
FIG. 5.
The role of the I domain in subcellular fractionation of
Gag. (A) Membrane-enriched fractions. The protein content of
membrane-enriched and soluble fractions generated by differential
sedimentation experiments was determined by fluorescence
spectrophotometry. Sample measurements were compared to a standard
curve generated from recombinant EGFP. The percentage of protein
present in the membrane-enriched pellet was calculated as the amount of
protein in the pellet/(the amount of protein in the soluble fraction
plus the amount of protein in the pellet). The results are the means of
three independent experiments for each construct. The error bars each
represent one SD from the mean. (B) Triton X-100-resistant pelleting.
0.5% Triton X-100 was added to the S1 supernatants prior to
centrifugation at 100,000 × g. The amount of the
Gag-GFP fusion protein present in the resulting detergent-resistant
pellet was quantitated by fluorescence spectrophotometry. The
percentage of protein present in the Triton X-100-resistant pellet was
calculated as the amount of protein in the pellet/(the amount of
protein in the soluble fraction plus the amount of protein in the
pellet). The results are means of three independent experiments for
each construct. The error bars each represent one SD from the mean. (C)
Quantitation of detergent-resistant pelleting of NC constructs
containing mutations of the N-terminal I domain (the R380/384A
mutation). The amount of Gag-GFP fusion protein found in the
detergent-resistant pellet was determined as described in the text.
|
|
The pellet generated from differential sedimentation centrifugation
contains not only the cellular membranes but also cytoskeletal proteins
and any cellular components with a high sedimentation value. Complexes
of Gag protein which would also sediment in these conditions may form
intracellularly. To determine what portion of the Gag protein found in
the membrane- and cytoskeleton-enriched pellet was due to membrane
binding versus cytoskeletal binding or Gag protein complex formation,
0.5% Triton X-100 was added to the S1 supernatant prior to
centrifugation at 100,000 × g. The detergent
solubilizes the membranes, and membrane-associated proteins are thus
shifted to the soluble fraction. Very little MA/GFP was found in the
detergent-resistant pellet. Extension of the Gag sequence to include
MA, CA, and SP1 (GAG377/GFP) did not significantly alter the amount of
Gag protein found in the detergent-resistant fraction (Fig. 5B).
Addition of the N-terminal I domain, however, significantly increased
the percentage of protein found in the detergent-resistant pellet
(P = 0.001 by Student's t test for
GAG377/GFP versus GAG384/GFP). There was a further increase in the mean
amount of detergent-resistant Gag protein upon the addition of the
first zinc finger (GAG405/GFP). This result is consistent with the
finding that inclusion of the first zinc finger was able to restore
dense particle formation to the N-terminal I domain mutant (Fig. 4) and
suggests that the two phenomena may be linked. The efficiency with
which Gag proteins sedimented in the presence of detergent increased
sequentially upon addition of the first zinc finger (GAG405/GFP), the
basic linker region (GAG411/GFP), and the second zinc finger
(GAG426/GFP). However, differences in the efficiency of sedimentation
between GAG405/GFP, GAG411/GFP, and GAG426/GFP did not reach
statistical significance. Addition of the C-terminal region of NC
(GAG432/GFP) decreased the amount of detergent-resistant pelleting
slightly, although this difference also did not reach statistical
significance (P = 0.474 by Student's t test
for GAG426/GFP versus GAG432/GFP). The efficient sedimentation of Gag
in the presence of nonionic detergent thus correlated closely with I
domain function as determined by the density of released particles.
Mapping the domains within NC that contribute to
detergent-resistant complex formation.
In order to determine which
of the subdomains of NC contributes to the ability of Gag to form
detergent-resistant complexes, we utilized the constructs already
described which contain an R380,384A substitution. These constructs
were expressed in BSC-40 cells, and differential sedimentation was
performed following the addition of Triton X-100. The R380,384A
mutations that were noted to disrupt I domain function in the density
assays also dramatically altered the ability of the Gag-GFP fusion
protein to sediment in the detergent-resistant pellet [as shown by a
comparison of the results for GAG384/GFP and
GAG384(R380,384A)/GFP (Fig. 5C)]. GAG384(R380,384A)/GFP
showed a marked decrease in the detergent-resistant pelleting compared
to wild-type GAG384/GFP, from a mean of 44% for the wild type to 18%
for the mutant, which is similar to I domain-deficient constructs
(MA/GFP and GAG377/GFP). Next we measured the amount of Gag-GFP fusion
protein found in the detergent-resistant pellet for constructs
representing the addition of individual subdomains of NC in the context
of the N-terminal I domain mutations (Fig. 5C). Addition of the
remaining portion of the N-terminal region of NC
(GAG391(R380,384A/GFP) led to an increase in sedimented Gag
protein; however, it was still significantly lower than GAG384/GFP with
an intact N-terminal I domain segment. The addition of the first zinc
finger [GAG405(R380,384A)/GFP] resulted in levels of detergent-resistant pelleting comparable to the levels of GAG384/GFP. A
stepwise increase in the percentage of the fusion protein was found in
the detergent-resistant pellet upon expression of each additional
subdomain of NC in the construct, with the exception of the C-terminal
domain [represented by GAG432(R380,384A)/GFP]. It is interesting to
note that only with the addition of the second zinc finger
[GAG426(R380,384A)/GFP] does the percentage of protein in the
detergent-resistant pellet reach the maximum value seen for this series
of Gag truncation constructs, suggesting that the effects of each
subdomain upon formation of Gag protein detergent-resistant complexes
were additive.
Subcellular localization of Gag proteins visualized by confocal
microscopy.
Members of our group have previously noted that
Gag-GFP constructs containing an I domain are found in distinct foci
underlying the plasma membrane, while Gag-GFP constructs lacking the I
domain are distributed more diffusely within the cellular cytoplasm
(29). We reasoned that if altered cellular distribution
represents a true function contributed by the I domain, then a
redistribution of Gag protein would be apparent for mutants that
disrupt the function of the N-terminal I domain. Laser confocal
microscopy was performed to examine the localization of the Gag-GFP
fusion protein constructs in living cells (Fig.
6). Constructs that lacked the I domain
demonstrated a diffuse distribution throughout the cytoplasm of the
cell. This was apparent for all constructs lacking the I domain as
previously reported (MA/GFP, GAGP/GFP, and MACA/GFP [29]), and is represented in Fig. 6A by GAG377/GFP.
Addition of the N-terminal I domain resulted in a transition to plasma membrane localization (GAG384/GFP [Fig. 6B]). We noted that for the
minimal I domain construct, GAG384/GFP, the membrane localization is
not complete. There is a fraction of diffuse, cytoplasmic localization and a fraction of punctate, peripheral membrane localization (Fig. 6B).
Expression of additional subdomains within NC resulted in more complete
plasma membrane localization, as demonstrated by GAG426/GFP (Fig. 6C).
These results are consistent with previous findings (29) and
appear to correlate with the amount of Gag protein present in
detergent-resistant complexes (i.e., those constructs with the highest
percentage of detergent-resistant complex demonstrate a higher
percentage of peripheral, punctate Gag protein). Next, we sought to
determine the effect of the N-terminal I domain mutations on the
localization of the Gag-GFP fusion protein. Cells expressing
GAG384(R380,384A)/GFP demonstrated a diffuse, cytoplasmic distribution
of the protein (Fig. 6D). Therefore, disruption of the I domain not
only alters particle density, it also affects Gag protein subcellular
localization as revealed by confocal microscopy. Addition of the
remaining segment of the N-terminal region of NC and the N-terminal
zinc finger led to a redistribution of Gag to distinct foci at the
plasma membrane [GAG405(R380,384A)/GFP (Fig. 6E)]. This result is
consistent with the finding that the first zinc finger restored dense
particle formation and detergent-resistant complex formation to the
N-terminal I domain mutant. These observations suggest that the effects
of the I domain upon particle density, detergent-resistant complex formation, and the presence of Gag in focal sites at the plasma membrane are tightly linked.


View larger version (163K):
[in this window]
[in a new window]
|
FIG. 6.
Influence of the I domain upon Gag-GFP subcellular
localization as determined by laser scanning confocal microscopy.
Digital images of live BSC-40 cells expressing the indicated Gag-GFP
fusion proteins were acquired with a Zeiss LSM410 laser confocal
microscope using the 40× objective. Images were obtained 5 h
after transfection with the indicated construct. The individual cells
shown are representative of over 75% of Gag-GFP-expressing cells
viewed for each construct. (A) GAG377/GFP; (B) GAG384/GFP; (C)
GAG426/GFP; (D) GAG384(R380/384A)/GFP; (E) GAG405(R380/384A)/GFP.
|
|
RVLP formation elicited by Gag-GFP fusion constructs.
In order
to determine the morphology of the light and dense retroviral particles
described in this study, electron microscopic analysis of cells
expressing representative constructs was performed. 55GAG/GFP
expression yielded retrovirus-like particles that were readily detected
budding from the plasma membrane of cells (Fig. 7A). The particles were 120 to 140 nm in
diameter, slightly larger than the expected size of 110 to 130 nm. In
many of the examined sections, 55GAG/GFP particles demonstrated an
irregular dense border which suggested clumping of the Gag-GFP protein
around the perimeter of the immature particles (Fig. 7B). The
expression construct containing the minimal NC sequence required for I
domain function, GAG384/GFP, produced RVLPs which were abundant and
largely indistinguishable from wild-type Gag RVLPs (Fig. 7C). No
irregular clumping of Gag protein within RVLPs as seen with 55GAG/GFP
was observed with this construct. In sharp contrast to these results, no particles consistent with RVLPs were observed with the constructs lacking I domain function, including GAG384(R380,384A)/GFP, GAG377/GFP, and MA/GFP (data not shown). Collections of vesicular material surrounding the cells were demonstrable in these preparations (data not
shown), and occasional spherical particles with a dense border were
observed (as shown for cells expressing MA/GFP in Fig. 7D). Notably,
these particles were smaller in diameter (90 to 100 nm) and lacked the
thick peripheral layer of Gag protein typical of Gag RVLPs (Fig. 7,
compare panels C and D). The association of these atypical particles
with Gag protein was not proven in the present study. In order to
determine if our inability to demonstrate RVLP production by I
domain-deficient Gag was merely due to inefficient particle release,
the amount of Gag-GFP protein released from cells expressing four of
the Gag-GFP constructs was measured by microplate fluorometry. With the
amount of released 55GAG/GFP set at 100% as a reference value, the
following results were obtained (means ± standard deviations
[SD] from three separate experiments): for GAG432/GFP, 22% ± 8%; for GAG384/GFP, 19 ± 11%; for GAG377/GFP, 13.2% ± 8%; and for MA/GFP, 12 ± 6%. Because the amount of released Gag
protein differed only twofold between an I domain-containing construct
that demonstrated numerous RVLPs by electron microscopy (GAG384/GFP)
and those demonstrating no evident RVLPs (GAG377/GFP and MA/GFP), it is
unlikely that inefficient production or release accounted for the
absence of observed RVLPs in this study. These results suggest that the
light particles formed by Gag proteins lacking I domain function in our
study may not be found associated with true RVLPs but may represent Gag
proteins released in some other form (such as in association with
cellular vesicles).

View larger version (127K):
[in this window]
[in a new window]
|
FIG. 7.
Electron microscopy of Gag-GFP particles. (A) 55GAG/GFP;
(B) 55GAG/GFP; (C) GAG384/GFP; (D) MA/GFP. Arrow indicates particle of
uncertain nature discussed in Results. Magnification, ×51,250.
Bar = 195 nm.
|
|
 |
DISCUSSION |
Localization of the N-terminal I domain.
The N-terminal I
domain was localized in this study to the N-terminal seven amino acids
of NC. Although it is surprising that such a discrete, small domain was
sufficient to confer upon the 377-amino-acid Gag molecule a dramatic
shift in particle density, the existence of a domain essential for
particle assembly located in the extreme N terminus of NC has been
previously reported (14, 18, 20). Our results extend this
finding and link this particle assembly domain to the function of the I
domain. The finding that two basic residues within this small region
are required for I domain function is consistent with the report that
addition of a small string of basic amino acids to a truncated RSV Gag
protein restored dense particle formation (2). However,
substitution of lysine residues in these positions in our study failed
to completely reconstitute normal particle density as predicted. These
data suggest that charge alone is insufficient to reconstitute I domain function, at least in this context, or that a particular arginine (R384) may play a more specific role which is not recreated by lysine
substitution. It is also interesting to note that the single substitution of R384 altered particle density to a greater degree than
that of the single substitution of R380. R384 (R7 in the NCp7 protein)
has recently been shown to make critical electrostatic interactions
with a homopolymeric RNA template by fluorescence spectroscopy
(33), and it is possible that this interaction is important
in I domain function.
I domain and Gag protein detergent-resistant complex
formation.
The ability of Gag to form intracellular Triton
X-100-resistant complexes has recently been identified in HIV-infected
cells and is proposed to represent an assembly intermediate (21,
22). Data from the present study indicate that detergent
resistance is mediated by the I domain. In the presence of N-terminal I
domain mutants, detergent-resistant sedimentation is enhanced
sequentially by the addition of further subdomains of NC, including the
addition of the remainder of the N-terminal subdomain, the N-terminal
zinc finger, the basic linker region, and the second zinc finger. Taken together, these data suggest that I domain function in the intact Gag
polyprotein is contributed by each of these four subdomains of NC. A
threshold amount of I domain activity is required to allow particles of
normal density to form; this may be contributed by the N-terminal I
domain alone or by the N-terminal zinc finger in the absence of
N-terminal I domain activity. Additional combinations of I domain
functional units from subdomains other than the N-terminal I domain and
the first zinc finger, must also be sufficient based upon data from
studies with RSV-HIV Gag chimeric proteins (1). Thus, there
are at least three functional I domain units within HIV-1 NC.
I domain and Gag subcellular localization.
The contribution of
the I domain to Gag protein subcellular localization in our studies is
somewhat enigmatic. It is clear that the M domain is required for
plasma membrane localization of Gag, yet the I domain enhanced the
peripheral localization of Gag dramatically in these studies. However,
disruption of the M domain by elimination of the myristylation site
abolishes any apparent contribution of the I domain to peripheral
localization of Gag (29). These findings are best reconciled
by the hypothesis that while the M domain is required for membrane
localization of Gag, the I domain enhances the efficiency of membrane
interaction or acts to stabilize the interaction. This may occur
through cooperative effects upon membrane binding: as multiple Gag
molecules interact in a coordinated fashion, a membrane-binding unit of
enhanced binding energy is formed (illustrated in Fig.
8). In the absence of the I domain, the
weak membrane-binding energy of Gag monomers is insufficient to
maintain the interaction and the molecule dissociates from the
membrane. Alternatively, the I domain may act to provide a trigger for
the myristyl switch present within MA. According to this hypothesis,
Gag-Gag interactions contributed by the I domain lead to a
conformational change within MA. The conformational change then results
in a more favorable presentation of myristic acid for membrane
interaction (Fig. 8). Several groups have now provided supporting data
for the presence of the myristyl switch within MA (25, 26, 30,
43). However, it remains to be demonstrated how direct Gag-Gag
interactions, which are most likely mediated by the CA-CA dimer
interface, with a possible contribution from NC (3, 9),
could result in a conformational change in the M domain. Solved
structures of MA reveal a long C-terminal helix through which such a
conformational change would have to be transmitted (17, 24),
and cryoelectron microscopy studies have demonstrated a significant
distance (approximately 70 Å) between the radial densities
corresponding to the MA globular domain and the C-terminal domain of CA
(11).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
Proposed model for I domain function. Gag monomers bind
to an RNA molecule through the I domain, which is located in multiple
subdomains of NC. The RNA then acts as a tether to allow Gag-Gag
multimerization to take place. Multimerization creates an intermediate
structure that has enhanced membrane binding energy by bringing
together multiple M domains in a common orientation (top right). An
alternative possibility to explain enhanced membrane association is
illustrated on the bottom right. According to this model, the myristyl
switch within MA is triggered through the influence of the I domain,
making myristic acid available for membrane interactions.
|
|
Nature of light Gag particles.
The nature of the Gag particles
lacking I domains (such as GAG377/GFP and MA/GFP) is not clear. We and
others have previously shown that HIV-1 Gag constructs lacking all of
NC are released, sediment through a sucrose cushion, and attain an
equilibrium density of 1.10 to 1.14 g/ml when analyzed by equilibrium
density centrifugation (6, 29, 41), and these results agree
with the description of light particles produced by RSV Gag in the absence of the I domain (1). It should be noted that the
efficiency of particle release in the absence of NC is diminished
(6, 41). In this study, we failed to demonstrate by electron
microscopy any apparent RVLPs budding from cells expressing truncated
Gag-GFP proteins that lack the I domain, a result which could not be
accounted for by observed differences in the amount of Gag released.
This striking lack of RVLP formation suggests that for HIV-1 Gag, the I
domain may be a required domain for RVLP formation itself. The released
Gag protein of light density may represent Gag protein associated with
cellular microvesicles, a hypothesis worthy of further study.
Alternatively, Gag proteins lacking the I domain may form aberrant
particles that lack the characteristic electron microscopic appearance
of RVLPs.
Role of RNA binding in I domain function.
In vitro models of
retroviral particle assembly have implicated the RNA binding function
within NC as an important determinant of particle assembly (4,
5). Also in support of a critical role for RNA is a recent report
that Gag-Gag multimerization requires RNA interaction and that RNase
can disrupt Gag-Gag interaction in vitro (3). We favor a
model of I domain function in which RNA binding is contributed by the I
domain, and RNA binding then facilitates Gag-Gag multimerization. The
RNA binding relevant to the present study must be nonspecific binding,
as our Gag constructs did not include the RNA packaging
(psi) region of the genome. The fact that the R384 residue
which was shown here to be important for N-terminal I domain function
has been identified as one of four key residues within NC involved in
critical electrostatic contacts with a homopolymeric RNA template
supports this model. Additional key residues for nonspecific RNA
binding are located within the N-terminal zinc finger and the
C-terminal zinc finger (33). Taken together, our data fit
with a model in which multiple regions of NC act concomitantly to bind
RNA and in which RNA binding then facilitates Gag-Gag interaction and
dense particle formation. Further investigation into the mechanism by
which the I domain contributes to dense particle formation will be
needed and is expected to yield important insights into the assembly
process of retroviruses.
 |
ACKNOWLEDGMENTS |
We acknowledge the Cell Imaging Core Laboratory of the
Vanderbilt-Ingram Cancer Center at Vanderbilt University for assistance with confocal microscopy, the Sequencing Core Laboratory of the Vanderbilt-Ingram Cancer Center for assistance with automated sequencing of expression plasmid inserts, and the Electron Microscopy Laboratory of the Department of Pathology at Vanderbilt University for
assistance with obtaining electron micrographs. We thank Terry Dermody
for critical evaluation of this manuscript prior to submission. Plasmid
pHIV-gpt was obtained from Kathleen Page and Dan Littman through the
NIH AIDS Research and Reference Reagent Program.
This work was supported by NIH grants AI40338 (P.S.), AI44369 (P.S.),
and AI45210 (V.V. and S.S.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Pediatric
Infectious Diseases, Vanderbilt University, D-7235 MCN, Nashville, TN
37232-2581. Phone: (615) 322-2250. Fax: (615) 343-9723. E-mail:
paul.spearman{at}mcmail.vanderbilt.edu.
 |
REFERENCES |
| 1.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 2.
|
Bowzard, J. B.,
R. P. Bennett,
N. K. Krishna,
S. M. Ernst,
A. Rein, and J. W. Wills.
1998.
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue.
J. Virol.
72:9034-9044[Abstract/Free Full Text].
|
| 3.
|
Burniston, M. T.,
A. Cimarelli,
J. Colgan,
S. P. Curtis, and J. Luban.
1999.
Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid- dimer interface and the basic region of matrix protein.
J. Virol.
73:8527-8540[Abstract/Free Full Text].
|
| 4.
|
Campbell, S., and A. Rein.
1999.
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.
J. Virol.
73:2270-2279[Abstract/Free Full Text].
|
| 5.
|
Campbell, S., and V. M. Vogt.
1995.
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.
J. Virol.
69:6487-6497[Abstract].
|
| 6.
|
Dawson, L., and X. F. Yu.
1998.
The role of nucleocapsid of HIV-1 in virus assembly.
Virology
251:141-157[CrossRef][Medline].
|
| 7.
|
Dorfman, T.,
A. Bukovsky,
A. Ohagen,
S. Hoglund, and H. G. Gottlinger.
1994.
Functional domains of the capsid protein of human immunodeficiency virus type 1.
J. Virol.
68:8180-8187[Abstract/Free Full Text].
|
| 8.
|
Erdie, C. R., and J. W. Wills.
1990.
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells.
J. Virol.
64:5204-5208[Abstract/Free Full Text].
|
| 9.
|
Franke, E. K.,
H. E. Yuan,
K. L. Bossolt,
S. P. Goff, and J. Luban.
1994.
Specificity and sequence requirements for interactions between various retroviral Gag proteins.
J. Virol.
68:5300-5305[Abstract/Free Full Text].
|
| 10.
|
Freed, E. O.
1998.
HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology
251:1-15[CrossRef][Medline].
|
| 11.
|
Fuller, S. D.,
T. Wilk,
B. E. Gowen,
H. G. Krausslich, and V. M. Vogt.
1997.
Cryoelectron microscopy reveals ordered domains in the immature HIV-1 particle.
Curr. Biol.
7:729-738[CrossRef][Medline].
|
| 12.
|
Garnier, L.,
J. B. Bowzard, and J. W. Wills.
1998.
Recent advances and remaining problems in HIV assembly.
AIDS
12:S5-S16.
|
| 13.
|
Garnier, L.,
L. J. Parent,
B. Rovinski,
S. X. Cao, and J. W. Wills.
1999.
Identification of retroviral late domains as determinants of particle size.
J. Virol.
73:2309-2320[Abstract/Free Full Text].
|
| 14.
|
Gheysen, D.,
E. Jacobs,
F. de Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. De Wilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.
Cell
59:103-112[CrossRef][Medline].
|
| 15.
|
Gitti, R. K.,
B. M. Lee,
J. Walker,
M. F. Summers,
S. Yoo, and W. I. Sundquist.
1996.
Structure of the amino-terminal core domain of the HIV-1 capsid protein.
Science
273:231-235[Abstract].
|
| 16.
|
Gottlinger, H. G.,
T. Dorfman,
J. G. Sodroski, and W. A. Haseltine.
1991.
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.
Proc. Natl. Acad. Sci. USA
88:3195-3199[Abstract/Free Full Text].
|
| 17.
|
Hill, C. P.,
D. Worthylake,
D. P. Bancroft,
A. M. Christensen, and W. I. Sundquist.
1996.
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
Proc. Natl. Acad. Sci. USA
93:3099-3104[Abstract/Free Full Text].
|
| 18.
|
Hoshikawa, N.,
A. Kojima,
A. Yasuda,
E. Takayashiki,
S. Masuko,
J. Chiba,
T. Sata, and T. Kurata.
1991.
Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study.
J. Gen. Virol.
72:2509-2517[Abstract/Free Full Text].
|
| 19.
|
Hunter, E.
1994.
Macromolecular interactions in the assembly of HIV and other retroviruses.
Semin. Virol.
5:71-83.
|
| 20.
|
Jowett, J. B.,
D. J. Hockley,
M. V. Nermut, and I. M. Jones.
1992.
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
J. Gen. Virol.
73:3079-3086[Abstract/Free Full Text]. (Erratum, 74:943, 1993.)
|
| 21.
|
Lee, Y. M.,
B. Liu, and X. F. Yu.
1999.
Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes.
J. Virol.
73:5654-5662[Abstract/Free Full Text].
|
| 22.
|
Lee, Y. M., and X. F. Yu.
1998.
Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells.
Virology
243:78-93[CrossRef][Medline].
|
| 23.
|
Mammano, F.,
A. Ohagen,
S. Hoglund, and H. G. Gottlinger.
1994.
Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis.
J. Virol.
68:4927-4936[Abstract/Free Full Text].
|
| 24.
|
Massiah, M. A.,
D. Worthylake,
A. M. Christensen,
W. I. Sundquist,
C. P. Hill, and M. F. Summers.
1996.
Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly.
Protein Sci.
5:2391-2398[Abstract].
|
| 25.
|
Ono, A., and E. O. Freed.
1999.
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.
J. Virol.
73:4136-4144[Abstract/Free Full Text].
|
| 26.
|
Paillart, J.-C., and H. G. Göttlinger.
1999.
Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of Gag membrane targeting.
J. Virol.
73:2604-2612[Abstract/Free Full Text].
|
| 27.
|
Parent, L. J.,
R. P. Bennett,
R. C. Craven,
T. D. Nelle,
N. K. Krishna,
J. B. Bowzard,
C. B. Wilson,
B. A. Puffer,
R. C. Montelaro, and J. W. Wills.
1995.
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
69:5455-5460[Abstract].
|
| 28.
|
Reicin, A. S.,
A. Ohagen,
L. Yin,
S. Hoglund, and S. P. Goff.
1996.
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle.
J. Virol.
70:8645-8652[Abstract].
|
| 29.
|
Sandefur, S.,
V. Varthakavi, and P. Spearman.
1998.
The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag.
J. Virol.
72:2723-2732[Abstract/Free Full Text].
|
| 30.
|
Spearman, P.,
R. Horton,
L. Ratner, and I. Kuli-Zade.
1997.
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism.
J. Virol.
71:6582-6592[Abstract].
|
| 31.
|
Spearman, P.,
J. J. Wang,
N. Vander Heyden, and L. Ratner.
1994.
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.
J. Virol.
68:3232-3242[Abstract/Free Full Text].
|
| 32.
|
Swanstrom, R., and J. W. Wills.
1997.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 33.
|
Urbaneja, M. A.,
B. P. Kane,
D. G. Johnson,
R. J. Gorelick,
L. E. Henderson, and J. R. Casas-Finet.
1999.
Binding properties of the human immunodeficiency virus type 1 nucleocapsid protein p7 to a model RNA: elucidation of the structural determinants for function.
J. Mol. Biol.
287:59-75[CrossRef][Medline].
|
| 34.
|
Verderame, M. F.,
T. D. Nelle, and J. W. Wills.
1996.
The membrane-binding domain of the Rous sarcoma virus Gag protein.
J. Virol.
70:2664-2668[Abstract].
|
| 35.
|
von Poblotzki, A.,
R. Wagner,
M. Niedrig,
G. Wanner,
H. Wolf, and S. Modrow.
1993.
Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation.
Virology
193:981-985[CrossRef][Medline].
|
| 36.
|
von Schwedler, U. K.,
T. L. Stemmler,
V. Y. Klishko,
S. Li,
K. H. Albertine,
D. R. Davis, and W. I. Sundquist.
1998.
Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly.
EMBO J.
17:1555-1568[CrossRef][Medline].
|
| 37.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function, and use of retroviral gag proteins.
AIDS
5:639-654[Medline].
|
| 38.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus Gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 39.
|
Yoo, S.,
D. G. Myszka,
C. Yeh,
M. McMurray,
C. P. Hill, and W. I. Sundquist.
1997.
Molecular recognition in the HIV-1 capsid/cyclophilin A complex.
J. Mol. Biol.
269:780-795[CrossRef][Medline].
|
| 40.
|
Zhang, W. H.,
D. J. Hockley,
M. V. Nermut,
Y. Morikawa, and I. M. Jones.
1996.
Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly.
J. Gen. Virol.
77:743-751[Abstract/Free Full Text].
|
| 41.
|
Zhang, Y., and E. Barklis.
1997.
Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation.
J. Virol.
71:6765-6776[Abstract].
|
| 42.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
| 43.
|
Zhou, W., and M. D. Resh.
1996.
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.
J. Virol.
70:8540-8548[Abstract].
|
Journal of Virology, August 2000, p. 7238-7249, Vol. 74, No. 16
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhou, Y., Rong, L., Lu, J., Pan, Q., Liang, C.
(2008). Insulin-Like Growth Factor II mRNA Binding Protein 1 Associates with Gag Protein of Human Immunodeficiency Virus Type 1, and Its Overexpression Affects Virus Assembly. J. Virol.
82: 5683-5692
[Abstract]
[Full Text]
-
Larsen, L. S. Z., Beliakova-Bethell, N., Bilanchone, V., Zhang, M., Lamsa, A., DaSilva, R., Hatfield, G. W., Nagashima, K., Sandmeyer, S.
(2008). Ty3 Nucleocapsid Controls Localization of Particle Assembly. J. Virol.
82: 2501-2514
[Abstract]
[Full Text]
-
Popov, S., Popova, E., Inoue, M., Gottlinger, H. G.
(2008). Human Immunodeficiency Virus Type 1 Gag Engages the Bro1 Domain of ALIX/AIP1 through the Nucleocapsid. J. Virol.
82: 1389-1398
[Abstract]
[Full Text]
-
Kenney, S. P., Lochmann, T. L., Schmid, C. L., Parent, L. J.
(2008). Intermolecular Interactions between Retroviral Gag Proteins in the Nucleus. J. Virol.
82: 683-691
[Abstract]
[Full Text]
-
Li, H., Dou, J., Ding, L., Spearman, P.
(2007). Myristoylation Is Required for Human Immunodeficiency Virus Type 1 Gag-Gag Multimerization in Mammalian Cells. J. Virol.
81: 12899-12910
[Abstract]
[Full Text]
-
Burnett, A., Spearman, P.
(2007). APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker. J. Virol.
81: 5000-5013
[Abstract]
[Full Text]
-
Casacuberta, E., Marin, F. A., Pardue, M.-L.
(2007). Intracellular targeting of telomeric retrotransposon Gag proteins of distantly related Drosophila species. Proc. Natl. Acad. Sci. USA
104: 8391-8396
[Abstract]
[Full Text]
-
Mannigel, I., Stange, A., Zentgraf, H., Lindemann, D.
(2007). Correct Capsid Assembly Mediated by a Conserved YXXLGL Motif in Prototype Foamy Virus Gag Is Essential for Infectivity and Reverse Transcription of the Viral Genome. J. Virol.
81: 3317-3326
[Abstract]
[Full Text]
-
Gomez, C. Y., Hope, T. J.
(2006). Mobility of Human Immunodeficiency Virus Type 1 Pr55Gag in Living Cells.. J. Virol.
80: 8796-8806
[Abstract]
[Full Text]
-
Saad, J. S., Miller, J., Tai, J., Kim, A., Ghanam, R. H., Summers, M. F.
(2006). From the Cover: Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. USA
103: 11364-11369
[Abstract]
[Full Text]
-
Booth, A. M., Fang, Y., Fallon, J. K., Yang, J.-M., Hildreth, J. E.K., Gould, S. J.
(2006). Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane.. J. Cell Biol.
172: 923-935
[Abstract]
[Full Text]
-
Lingappa, J. R., Dooher, J. E., Newman, M. A., Kiser, P. K., Klein, K. C.
(2006). Basic Residues in the Nucleocapsid Domain of Gag Are Required for Interaction of HIV-1 Gag with ABCE1 (HP68), a Cellular Protein Important for HIV-1 Capsid Assembly. J. Biol. Chem.
281: 3773-3784
[Abstract]
[Full Text]
-
Alfadhli, A., Dhenub, T. C., Still, A., Barklis, E.
(2005). Analysis of Human Immunodeficiency Virus Type 1 Gag Dimerization-Induced Assembly. J. Virol.
79: 14498-14506
[Abstract]
[Full Text]
-
Ott, D. E., Coren, L. V., Gagliardi, T. D.
(2005). Redundant Roles for Nucleocapsid and Matrix RNA-Binding Sequences in Human Immunodeficiency Virus Type 1 Assembly. J. Virol.
79: 13839-13847
[Abstract]
[Full Text]
-
Ono, A., Waheed, A. A., Joshi, A., Freed, E. O.
(2005). Association of Human Immunodeficiency Virus Type 1 Gag with Membrane Does Not Require Highly Basic Sequences in the Nucleocapsid: Use of a Novel Gag Multimerization Assay. J. Virol.
79: 14131-14140
[Abstract]
[Full Text]
-
Dye, B. T., Miller, D. J., Ahlquist, P.
(2005). In Vivo Self-Interaction of Nodavirus RNA Replicase Protein A Revealed by Fluorescence Resonance Energy Transfer. J. Virol.
79: 8909-8919
[Abstract]
[Full Text]
-
Klein, K. C., Dellos, S. R., Lingappa, J. R.
(2005). Identification of Residues in the Hepatitis C Virus Core Protein That Are Critical for Capsid Assembly in a Cell-Free System. J. Virol.
79: 6814-6826
[Abstract]
[Full Text]
-
Guo, X., Roldan, A., Hu, J., Wainberg, M. A., Liang, C.
(2005). Mutation of the SP1 Sequence Impairs both Multimerization and Membrane-Binding Activities of Human Immunodeficiency Virus Type 1 Gag. J. Virol.
79: 1803-1812
[Abstract]
[Full Text]
-
Muriaux, D., Costes, S., Nagashima, K., Mirro, J., Cho, E., Lockett, S., Rein, A.
(2004). Role of Murine Leukemia Virus Nucleocapsid Protein in Virus Assembly. J. Virol.
78: 12378-12385
[Abstract]
[Full Text]
-
Derdowski, A., Ding, L., Spearman, P.
(2004). A Novel Fluorescence Resonance Energy Transfer Assay Demonstrates that the Human Immunodeficiency Virus Type 1 Pr55Gag I Domain Mediates Gag-Gag Interactions. J. Virol.
78: 1230-1242
[Abstract]
[Full Text]
-
Tang, C., Loeliger, E., Luncsford, P., Kinde, I., Beckett, D., Summers, M. F.
(2004). From the Cover: Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc. Natl. Acad. Sci. USA
101: 517-522
[Abstract]
[Full Text]
-
Ma, Y. M., Vogt, V. M.
(2004). Nucleic Acid Binding-Induced Gag Dimerization in the Assembly of Rous